Pfizer ups drug prices

Share this article:
Industry analysts say average wholesale prices for Pfizer drugs such as Lipitor and Celebrex went up by more than 5%, Reuters reported. A Bear Stearns analyst quoted in the report said the price hike, effective Jan. 1, was somewhat more aggressive than price increases taken in each of the previous three years. He estimated the rise at 5.2%; a Merrill Lynch analyst pegged it at 5.6%. While cholesterol drug Lipitor and arthritis therapy Celebrex were included in the increase, newer drugs Chantix (smoking cessation) and Exubera (diabetes) were not. The 5% boost surprised some analysts, who said they had anticipated a lesser increase in light of political scrutiny over drug pricing expected this year. However, one analyst added, Pfizer may have raised prices sharply to make good on its prediction that 2007 revenue will match that seen last year.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.